ArticleTranslational lung cancer research2025
A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current standard of care for squamous non-small cell lung cancer (sqNSCLC) is not very effective, and FGFR2b-targeted therapy may be a new option for patients with sqNSCLC. The prevalence and clinical implications of fibroblast growth factor receptor 2b (FGFR2b) expression in Chinese patients with advanced sqNSCLC remain poorly characterized. This study evaluated FGFR2b expression patterns, their association with programmed death-ligand 1 (PD-L1) expression, and clinical outcomes in this population. Methods: This retrospective cross-sectional analysis screened three hundred newly diagnosed advanced sqNSCLC patients from 2018 to 2024. Archival biopsy samples were assessed for FGFR2b expression via immunohistochemistry (IHC). A total of 266 patients, with histologically confirmed stage IIIB-IV sqNSCLC and valid FGFR2b protein expression status, were enrolled. Historical clinical data and PD-L1 detection reports were extracted from hospital records. Results: Among the 266 patients, 117 (44.0%, 117/266) were diagnosed with IIIB/IIIC-stage cancer, and 149 (56%, 149/266) were diagnosed with IV-stage cancer. FGFR2b positivity (≥1+ in ≥1% tumor cells) was observed in 50.8% of patients, while overexpression (≥2+ in ≥1% tumor cells) occurred in 19.5%. FGFR2b expression was correlated significantly with sex (P=0.04), and cancer stage (P=0.01). Among 204 patients with valid FGFR2b and PD-L1 dual expression data, over 80% of FGFR2b-positive tumors demonstrated concurrent PD-L1 expression. In patients receiving first-line paclitaxel/nab-paclitaxel-platinum combined with anti-programmed cell death-1 (PD-1)/PD-L1 antibodies, FGFR2b-positive cohorts exhibited superior outcomes: higher objective response rate (57.4% Conclusions: FGFR2b expression may serve as a predictive biomarker for therapeutic response of FGFR2b-targeted agents in sqNSCLC. The high co-expression rate of FGFR2b and PD-L1 supports the feasibility of combining FGFR2b-targeted agents with immune checkpoint inhibitors as a rational treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.